QIAGEN Long Term Debt 2010-2022 | QGEN

QIAGEN long term debt from 2010 to 2022. Long term debt can be defined as the sum of all long term debt fields.
  • QIAGEN long term debt for the quarter ending June 30, 2022 was $1.475B, a 23.94% decline year-over-year.
  • QIAGEN long term debt for 2021 was $1.094B, a 41.81% decline from 2020.
  • QIAGEN long term debt for 2020 was $1.88B, a 32.31% increase from 2019.
  • QIAGEN long term debt for 2019 was $1.421B, a 14.96% decline from 2018.
QIAGEN Annual Long Term Debt
(Millions of US $)
2021 $1,094
2020 $1,880
2019 $1,421
2018 $1,671
2017 $1,758
2016 $1,067
2015 $1,049
2014 $1,041
2013 $845
2012 $846
2011 $446
2010 $797
2009 $870
QIAGEN Quarterly Long Term Debt
(Millions of US $)
2022-06-30 $1,475
2022-03-31 $1,475
2021-12-31 $1,094
2021-09-30 $1,569
2021-06-30 $1,940
2021-03-31 $1,929
2020-12-31 $1,880
2020-09-30 $1,418
2020-06-30 $1,400
2020-03-31 $1,387
2019-12-31 $1,421
2019-09-30 $1,689
2019-06-30 $1,411
2019-03-31 $1,398
2018-12-31 $1,671
2018-09-30 $1,067
2018-06-30 $1,341
2018-03-31 $1,354
2017-12-31 $1,758
2017-09-30 $1,747
2017-06-30 $1,384
2017-03-31 $1,072
2016-12-31 $1,067
2016-09-30 $1,069
2016-06-30 $1,072
2016-03-31 $1,060
2015-12-31 $1,049
2015-09-30 $1,058
2015-06-30 $1,049
2015-03-31 $1,048
2014-12-31 $1,041
2014-09-30 $1,034
2014-06-30 $1,175
2014-03-31 $1,171
2013-12-31 $845
2013-09-30 $846
2013-06-30 $846
2013-03-31 $846
2012-12-31 $846
2012-09-30 $445
2012-06-30 $445
2012-03-31 $446
2011-12-31 $446
2011-09-30 $447
2011-06-30 $796
2011-03-31 $797
2010-12-31 $797
2010-09-30 $822
2010-06-30 $896
2010-03-31 $897
2009-12-31 $898
2009-09-30 $899
2009-06-30 $948
2009-03-31 $949
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $11.276B $2.252B
QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of proprietary, consumable products, and automated solutions for sample collection. Qiagen has subsidiaries several other countries with good sales potential. Segment Details Consumables: These are typically sample preparation or test kits that contain all the necessary reagents and buffers, and a manual including protocols and relevant background information. Automated Instruments: These automate the use of Sample & Assay Technologies into efficient solutions for a broad range of laboratory needs. Customer Classes: QIAGEN focuses on 4 principal segments or customer classes for sample and assay technologies:? Molecular Diagnostics, Applied Testing, Pharma and Academia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $159.141B 9.65
GSK (GSK) United Kingdom $71.077B 8.53
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
Biohaven Pharmaceutical Holding (BHVN) United States $10.581B 0.00
Ginkgo Bioworks Holdings (DNA) United States $6.200B 0.00
Arcus Biosciences (RCUS) United States $2.020B 39.44
Myovant Sciences (MYOV) United Kingdom $1.765B 0.00
Emergent Biosolutions (EBS) United States $1.521B 8.81
Zymeworks (ZYME) Canada $0.418B 0.00
Enzo Biochem (ENZ) United States $0.133B 0.00
Gelesis Holdings (GLS) United States $0.101B 0.00
SQZ Biotechnologies (SQZ) United States $0.099B 0.00
Ambrx Biopharma (AMAM) United States $0.095B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00